LICENSE, MARKETING AND DEVELOPMENT AGREEMENT BY AND BETWEEN ANTHROGENESIS CORPORATION, D/B/A CCT AND ALLIQUA, INC. NOVEMBER 14, 2013License, Marketing and Development Agreement • March 7th, 2014 • Celgene Corp /De/ • Pharmaceutical preparations • New York
Contract Type FiledMarch 7th, 2014 Company Industry JurisdictionThis LICENSE, MARKETING AND DEVELOPMENT AGREEMENT (the “Agreement”) is entered into as of November 14, 2013 (the “Effective Date”) by and between ANTHROGENESIS CORPORATION, D/B/A CELGENE CELLULAR THERAPEUTICS (“CCT”), a New Jersey corporation having a principal place of business at 33 Technology Drive, 2nd Floor, Warren, NJ 07059 (“CCT”), and ALLIQUA, INC., a Florida corporation having a principal place of business at 2150 Cabot Boulevard West, Langhorne, Pennsylvania (“Alliqua”). Alliqua and CCT may each be referred to as a “Party” or collectively be referred to as the “Parties”.
SUPPLY AGREEMENT BY AND BETWEEN ANTHROGENESIS CORPORATION AND ALLIQUA, INC. NOVEMBER 14, 2013Supply Agreement • March 7th, 2014 • Celgene Corp /De/ • Pharmaceutical preparations • New York
Contract Type FiledMarch 7th, 2014 Company Industry JurisdictionTHIS SUPPLY AGREEMENT (this “Agreement”) dated as of November 14, 2013 (the “Effective Date”), by and between Anthrogenesis Corporation, a Delaware corporation doing business as Celgene Cellular Therapeutics (“CCT”), and Alliqua, Inc., a Florida corporation (“Alliqua”). Alliqua and CCT may each be referred to as a “Party” or collectively be referred to as the “Parties”.